Corvus Pharmaceuticals Director Resigns: Ian T. Clark Effective Jul 22, 2026

What Happened
Corvus Pharmaceuticals, Inc. (CRVS) filed a Form 8-K (Item 5.02) announcing that director Ian T. Clark delivered notice of his resignation on July 21, 2026, with the resignation effective July 22, 2026. The company acknowledged Mr. Clark’s contribution after more than nine years of board service. The report was signed by CFO Leiv Lea on July 22, 2026.

Key Details

• Filing type: Form 8-K (Item 5.02 — Departure of Directors or Certain Officers).
• Resigning director: Ian T. Clark.
• Notice and effective dates: Notice delivered July 21, 2026; resignation effective July 22, 2026.
• Tenure: More than nine years of board service.
• Signed by: Leiv Lea, Chief Financial Officer, dated July 22, 2026.

Why It Matters
A board member resignation can affect corporate governance and voting dynamics on the board. This filing informs investors of the change in the board’s composition; however, the company did not announce any additional director appointments or changes to executive officers in this filing. Investors tracking governance, board independence, or potential committee reassignments should note the change and watch for any subsequent filings naming a replacement or describing impacts on board committees.